-

MindWalk CTO Dr. Dirk Van Hyfte to Join Fireside Chat at AI Drug Discovery & Development Summit 2025

AUSTIN, Texas--(BUSINESS WIRE)--MindWalk Holdings Corp.™ (“MindWalk,” “Company,” “we” or “us”) (Nasdaq: HYFT), a Bio-Native AI company, today announced that Dr. Dirk Van Hyfte, Chief Technology Officer, will participate in a fireside chat during the Biology Session at the AI Drug Discovery & Development Summit 2025, taking place on November 20, 2025, from 12:15 PM to 12:45 PM.

"His work exemplifies how scientific depth and data-driven design can come together to advance precision discovery.”

Share

The AI Drug Discovery & Development Summit is a premier event that brings together industry leaders, researchers, and innovators to explore how artificial intelligence is reshaping drug discovery pipelines and accelerating therapeutic development. Dr. Van Hyfte will share insights on how MindWalk’s HYFT®-powered LensAi™ platform is unlocking new opportunities to index, connect, and continuously update biological knowledge at scale—redefining how the industry approaches discovery and development.

“We’re pleased to see Dr. Van Hyfte representing MindWalk’s vision for Bio-Native AI and Deep Data internationally,” said Dr. Jennifer Bath, CEO of MindWalk. “His work exemplifies how scientific depth and data-driven design can come together to advance precision discovery.”

For more information on the event, visit the official website: AI Drug Discovery & Development Summit 2025

About MindWalk
MindWalk is a Bio-Native AI company transforming drug discovery and development. Powered by patented HYFT® technology and the LensAI™ platform, MindWalk unifies sequence, structure, function, and literature into a single computational language and closes the loop with an integrated, full-stack wet lab. The platform supports rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics that help turn insights into validated candidates at speed.

Source: MindWalk Holdings Corp.

Contacts

Investor Contact
Louie Toma, CPA, CFA
Managing Director, CoreIR
investors@mindwalkAI.com

Industry:

MindWalk Holdings Corp.

NASDAQ:HYFT
Release Versions
EnglishFrench
$Cashtags
$HYFT
Hashtags
#AI
#BIONATIVEAI
#DrugDiscovery
#TechBio
#llm

Contacts

Investor Contact
Louie Toma, CPA, CFA
Managing Director, CoreIR
investors@mindwalkAI.com

Social Media Profiles
Linkedin
MindWalk Holdings on X
More News From MindWalk Holdings Corp.

MindWalk Appoints R. Scott Areglado as Chief Financial Officer to Strengthen Financial Leadership and Support Growth Strategy

AUSTIN, Texas--(BUSINESS WIRE)--MindWalk Holdings Corp.™ (“MindWalk,” “Company,” “we” or “us”) (Nasdaq: HYFT), bio-native AI company today announces the appointment of industry veteran R. Scott Areglado as Chief Financial Officer (CFO), effective October 20, 2025. “Scott’s extensive experience leading financial strategy for high-growth, publicly traded healthcare and technology companies makes him an ideal addition to our executive team,” said Dr. Jennifer Bath, MindWalk CEO. “His proven abilit...

MindWalk Appoints Dr. Thomas W. Lynch as Chief Business Officer to Accelerate Commercial Expansion

AUSTIN, Texas--(BUSINESS WIRE)--MindWalk Holdings Corp.™ (“MindWalk,” “Company,” “we” or “us”) (Nasdaq: HYFT), a Bio-Native AI company today announced the appointment of industry veteran Thomas W. Lynch, Ph.D. as Chief Business Officer (CBO), effective October 20, 2025. “Tom’s combination of biotech depth and software commercialization expertise directly supports MindWalk’s next path of growth,” said Dr. Jennifer Bath CEO of MindWalk. “As we expand the reach of our HYFT-powered Deep Data platfo...

MindWalk Announces Share Repurchase Program

AUSTIN, Texas--(BUSINESS WIRE)--MindWalk Holdings Corp. (“MindWalk” or the “Company”) (NASDAQ: “HYFT”), a bio-native AI company, today announced that to underscore its confidence in MindWalk's future development and growth prospects, its Board of Directors (the “Board”) has authorized a share repurchase program under which MindWalk may repurchase up to 2.3 million common shares of the Company, no par value (the “Common Shares”) over the twelve-month period commencing on October 15th, 2025, and...
Back to Newsroom